Guillermo Garcia-Manero

Houston

Editorial Board at Blood Cancer Journal

Contributor at Journal of Clinical Oncology

Leukemia physician and Professor of Medicine and Chief of Section of MDS at MD Anderson Cancer Center. Leukemia, maybe some other stuff. All my own opinion.

Articles

Barriers to allogeneic stem cell transplantation in responding patients with TP53-mutated acute myeloid leukemia - Bone Marrow Transplantation

2 weeks ago | nature.com | Jayastu Senapati |Guillermo Garcia-Manero |Courtney DiNardo |Gautam Borthakur |Tapan M Kadia |Elias Jabbour | +8 more

Despite the improvement in overall outcomes of patients with acute myeloid leukemia (AML), some high-risk disease subsets continue to fare dismally. AML with TP53 aberrations (mutations, deletions) is one such subset of high-risk AML with a median survival of about 6–9 months [1,2,3].
VEN in combination with 10-day DEC in newly diagnosed elderly or relapsed/refractory acute myeloid leukemia, and high-risk myelodysplastic syndrome: long term follow-up of a phase 2 trial | Blood Cancer Journal

3 weeks ago | nature.com | Mahesh Swaminathan |Courtney DiNardo |Naveen Pemmaraju |Guillermo Garcia-Manero |Ghayas C. Issa |Gautam Borthakur | +9 more

To the Editor:The advent of VEN (VEN) has changed the treatment paradigm of acute myeloid leukemia (AML). Currently, venetoclax (VEN), in combination with a hypomethylating agent (HMA), is approved for the treatment of adult patients with AML unsuitable for intensive chemotherapy or frontline treatment of patients ≥75 years [1].
Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia | Leukemia

1 month ago | nature.com | Courtney DiNardo |Wei-Ying Jen |Koichi Takahashi |Tapan M Kadia |Sanam Loghavi |Patrick K. Reville | +19 more

AbstractIntensive chemotherapy remains the standard for newly diagnosed (ND) acute myeloid leukemia (AML); however, relapse risk remains high. Additionally, most patients with relapsed/refractory (RR) AML have poor outcomes. We report the long-term experience of 138 patients, 77 ND and 61 RR, treated with FLAG-IDA in combination with venetoclax.
Clinico‐Genomic Interrogation of Secondary‐Type Acute Myeloid Leukemia: Response and Outcomes to Contemporary Therapies

2 months ago | onlinelibrary.wiley.com | Jayastu Senapati |Sanam Loghavi |Jennifer Marvin-Peek |Guillermo Garcia-Manero

Conflicts of Interest The authors declare no conflicts of interest. Supporting Information Filename Description ajh27628-sup-0001-supinfo.docxWord 2007 document , 8.8 MB Data S1. Supporting Information. References 1, , , et al., “Genomic Classification and Prognosis in Acute Myeloid Leukemia,” New England Journal of Medicine 374, no. 23 (2016): 2209–2221, https://doi.org/10.1056/NEJMoa1516192.
Where Imetelstat Fits Into the Paradigm for Transfusion-Dependent Anemia in MDS

2 months ago | onclive.com | Amer M Zeidan |Guillermo Garcia-Manero

Where Imetelstat Fits Into the Paradigm for Transfusion-Dependent Anemia in MDSAmer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss the implications of the FDA approval of imetelstat for transfusion-dependent anemia in MDS.
The Importance of Treating Anemia in MDS

2 months ago | onclive.com | Amer M Zeidan |Guillermo Garcia-Manero

Comparable Survival Outcomes Observed With Atezolizumab/Bevacizumab vs Tremelimumab/Durvalumab in First-Line HCCDr Levy on the Development and Clinical Use of ADCs in NSCLC
The Potential of Oral HMAs in MDS

2 months ago | onclive.com | Amer M Zeidan |Guillermo Garcia-Manero

The Potential of Oral HMAs in MDSAmer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss the potential for the use of oral HMAs in MDS.
Dr Garcia-Manero on Dual IRAK4/FLT3 Inhibition With Emavusertib in MDS and AML

2 months ago | onclive.com | Guillermo Garcia-Manero

CommentaryVideoJanuary 27, 2025Author(s):Guillermo Garcia-Manero, MD, discusses the rationale for investigating the dual inhibition of IRAK4 and FLT3 with emavusertib in MDS and AML"We have developed a number of clinical trials for [emavusertib in] high-risk MDS and AML targeting different splice forms. In AML, [this research specifically] focused on FLT3 mutational status.
Academic Perspectives for LR-MDS Treatment in the Community

Jan 15, 2025 | targetedonc.com | Guillermo Garcia-Manero |David M. Swoboda

January 15, 2025By Panelists discuss key learnings from recent studies on lower-risk myelodysplastic syndrome (LR-MDS) treatment, identify remaining knowledge gaps, and offer final takeaways, including their thoughts on the role of luspatercept in the evolving LR-MDS treatment landscape, clinical pearls for community oncologists, and major unanswered questions that could improve outcomes for LR-MDS and anemia management in the future.
Sequencing Therapies in LR-MDS

Jan 15, 2025 | targetedonc.com | Guillermo Garcia-Manero |David M. Swoboda

January 15, 2025By Panelists discuss second-line (2L) treatment strategies for lower-risk myelodysplastic syndrome (LR-MDS), focusing on how to choose a 2L treatment for patients refractory to first-line options, and provide an overview of recent updates from the IMerge trial (Santini et al, EHA 2024; Zeidan et al, JCO 2024), while considering the role of imetelstat in treatment sequencing according to NCCN Guidelines MDS-5. Please give an overview of 2L treatment strategies.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →

X (formerly Twitter)

Followers: 3K
Tweets: 2K
DMs Open: No

G Garcia-Manero @garciamanero

13 Dec 22

So happy for Yasmin: congrats!

Jessica Altman, MD @jaltmanmd

Always proud of ⁦@yasminabaza1⁩! She is always pushing us to do better. Today she presented her work at #ASH22 on treatment of #AML with FLAG-ida + ven. ⁦Thank you ⁦@TalhaKhanRx⁩. ⁦@MartinTallman⁩ ⁦@LurieCancer⁩ ⁦@LeonidasPlatan1⁩ https://t.co/THibeZiI4r

G Garcia-Manero @garciamanero

13 Dec 22

RT @jayastuMD: 🙏🏼🙏🏼🙏🏼 Sincere thanks to @DrHKantarjian @garciamanero @TapKadia for your leadership and mentorship towards the comprehensive…

G Garcia-Manero @garciamanero

12 Dec 22

RT @kanagalshamanna: Thank you Aditi for the shoutout @aditishasMD ☺️

Guillermo Garcia-Manero

Articles

Barriers to allogeneic stem cell transplantation in responding patients with TP53-mutated acute myeloid leukemia - Bone Marrow Transplantation

VEN in combination with 10-day DEC in newly diagnosed elderly or relapsed/refractory acute myeloid leukemia, and high-risk myelodysplastic syndrome: long term follow-up of a phase 2 trial | Blood Cancer Journal

Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia | Leukemia

Clinico‐Genomic Interrogation of Secondary‐Type Acute Myeloid Leukemia: Response and Outcomes to Contemporary Therapies

Where Imetelstat Fits Into the Paradigm for Transfusion-Dependent Anemia in MDS

The Importance of Treating Anemia in MDS

The Potential of Oral HMAs in MDS

Dr Garcia-Manero on Dual IRAK4/FLT3 Inhibition With Emavusertib in MDS and AML

Academic Perspectives for LR-MDS Treatment in the Community

Sequencing Therapies in LR-MDS

Contact details

Emails

Socials & Sites

X (formerly Twitter)